Bell Potter last valued and wrote about IMU in September 2021. This was before the three new HErvaxx trials. So something has changed... they explain it here...
"Valuation is lowered to $0.45 from $0.52. The future deal value for HER-Vaxx is reduced modestly because the company is pursuing an initial 2nd line approval. An approval in 2nd line is likely to driver a lower deal value for HER-Vaxx."
Lower deal value - compared to what was considered with earlier HerVaxx trials.
Analysts Reports (Imugene), page-180
-
- There are more pages in this discussion • 159 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.6¢ |
Change
-0.002(4.17%) |
Mkt cap ! $342.1M | |||
| Open | High | Low | Value | Volume |
| 4.8¢ | 4.8¢ | 4.6¢ | $400.2K | 8.603M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 17 | 1876197 | 4.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.7¢ | 613421 | 6 |
View Market Depth
| Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |